Evidence map›Paper›PMID 27363431›Full record

ArticleRetrovirology2016

The effect of HIV-1 Vif polymorphisms on A3G anti-viral activity in an in vivo mouse model.

Cristhian Cadena, Spyridon Stavrou, Tomaz Manzoni, Shilpa S Iyer, Frederic Bibollet-Ruche, Weiyu Zhang, Beatrice H Hahn, Edward P Browne, Susan R Ross

Open access · goldAbstract read
In one paragraph

Article in Retrovirology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Cristhian CadenaDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Spyridon StavrouDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Tomaz ManzoniDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Shilpa S IyerDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Frederic Bibollet-RucheDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Weiyu ZhangDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Beatrice H HahnDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Edward P BrowneKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Susan R RossDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. srross@uic.edu.ORCID 0000-0002-3094-3769
University of Pennsylvania · USIllinois College · USUniversity of Illinois Chicago · USUniversity of North Carolina at Chapel Hill · US

Funding

TRAINING IN HIV PATHOGENESIST32AI007632 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Frederic D Bushman, James L. Riley · 2000 to 2026
$10.6M
UPenn Post Baccalaureate Research Education Program.R25GM071745 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI BHOJ, ELIZABETH JOYCE, KESSLER, DANIEL S · 2005 to 2024
$6.4M
Role of APOBEC3 in in vivo Restriction of Retrovirus InfectionR01AI085015 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ROSS, SUSAN R · 2010 to 2019
$3.9M
Restriction of HIV-1 transmission by type 1 interferonsR01AI114266 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HAHN, BEATRICE H · 2014 to 2018
$3.2M
Harnessing type 1 IFN-stimulated antiviral mechanisms for HIV vaccine designR01AI111789 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HAHN, BEATRICE H · 2014 to 2017
$816k
The in vivo function of A3A and A3G during retrovirus infectionF32AI100512 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI STAVROU, SPYRIDON · 2013 to 2013
$54k
NIAID NIH HHS F32 AI100512NIAID NIH HHS R01 AI085015NIAID NIH HHS R01 AI111789NIAID NIH HHS R01 AI114266NIAID NIH HHS T32 AI007632NIGMS NIH HHS R25 GM071745
6 · The paper itself

Abstract

Humans encode seven APOBEC3 proteins (A-H), with A3G, 3F and 3H as the major factors restricting HIV-1 replication. HIV-1, however, encodes Vif, which counteracts A3 proteins by chaperoning them to the proteasome where they are degraded. Vif polymorphisms found in HIV-1s isolated from infected patients have varying anti-A3G potency when assayed in vitro, but there are few studies demonstrating this in in vivo models. Here, we created Friend murine leukemia viruses encoding vif alleles that were previously shown to differentially neutralize A3G in cell culture or that were originally found in primary HIV-1 isolates. Infection of transgenic mice expressing different levels of human A3G showed that these naturally occurring Vif variants differed in their ability to counteract A3G during in vivo infection, although the effects on viral replication were not identical to those seen in cultured cells. We also found that the polymorphic Vifs that attenuated viral replication reverted to wild type only in A3G transgenic mice. Finally, we found that the level of A3G-mediated deamination was inversely correlated with the level of viral replication. This animal model should be useful for studying the functional significance of naturally occurring vif polymorphisms, as well as viral evolution in the presence of A3G.

Indexed as

Polymorphism, GeneticAllelesAnimalsAPOBEC-3G DeaminaseDisease Models, AnimalFriend murine leukemia virusHIV-1HIV InfectionsHumansMiceMice, TransgenicMutationvif Gene Products, Human Immunodeficiency VirusVirus ReplicationAPOBEC-3G DeaminaseAPOBEC3G protein, humanvif Gene Products, Human Immunodeficiency VirusAPOBEC3Cytidine deaminaseHIVMurine leukemia virusVif

Identifiers

PMID27363431
PMCPMC4929759
OpenAlexW2471837504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.